To determine whether VISTA may play a role in driving immune evasion in NPM1-mutant patients and to further explore the VISTA-mediated interplay between AML cells and T cells, we analyzed single-cell RNA-sequencing from matched patients with normal-karyotype AML, who underwent standard induction and consolidation chemotherapy and had long (LFR: absence of relapse over a follow-up period of >5 years) versus short remissions (SFR: relapse within 2 years) [5]. Here, VSIR is linked to acute myeloid leukemia.